Jones, RB, Hjelmeland, AB, and Bellis, SL. (2018) The ST6Gal-I sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1α signaling. J Biol Chem, 293: 5659-5667 |
|
Holdbrooks, AT, Britain, CM, Bellis, SL. (2018) ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor. J Biol Chem, 293: 1610-1622 |
|
Chakraborty, A, Dorsett, KA, Trummell, HQ, Yang, ES, Oliver, PG, Bonner, JA, Buchsbaum, DJ, Bellis, SL. (2018) ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. J Biol Chem, 293: 984-994 |
|
Britain, CM, Holdbrooks, AT, Anderson JC, Willey, CD, Bellis, SL (2018) Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death. J Ovarian Res, 11:12 |
|
Britain, CM, Dorsett, KA, Bellis, SL (2017) The tumor-associated glycosyltransferase ST6Gal-I protects tumor cells against serum growth factor withdrawal by enhancing survival signaling and proliferative potential. J Biol Chem 292: 4663-73 |
|
Schultz, MJ, Holdbrooks, AT, Chakraborty, A, Grizzle, WE, Landen, CN, Buchsbaum, DJ, Conner, MG, Arend, RC, Yoon, K, Klug, CA, Bullard, DC, Kesterson, RA, Oliver, PG, O’Conner, AK, Yoder, BK, Bellis, SL (2016) The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype. Cancer Res, 76: 3978-88 |
|
|